programs
PARP Inhibitors for Epithelial Ovarian Cancer
PARP Inhibitors for Epithelial Ovarian Cancer
Dr. Alon Altman summarizes the Canadian consensus paper on first-line PARPi maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.
RevealingNewDataIn_BC_May20_22.pptxHER2+ Metastatic Breast Cancer Paper: Canadian Perspective Program
HER2+ Metastatic Breast Cancer Paper: Canadian Perspective Program
Program summarizing the Canadian perspective paper on a new treatment algorithm for HER2+ Breast Cancer.
RevealingNewDataIn_BC_May20_22_FR.pptxTraitement du cancer du sein HER2-positif de stade avencé
Traitement du cancer du sein HER2-positif de stade avencé
Programme sur la tratement du cancer du sein HER2-positif.
MBC AE Nursing Program_April27_21.pptxHER2+ Metastatic Breast Cancer: Management of Adverse Events
HER2+ Metastatic Breast Cancer: Management of Adverse Events
Nursing program on managing AEs with ADCs and TKIs. Funding provided by AstraZeneca.
RWE Education program_FINAL_Dec5-19_FINAL.pptxReal-World Evidence in Inflammatory Arthritis
Real-World Evidence in Inflammatory Arthritis
Program highlighting real-world evidence in inflammatory arthritis.
SCNursingProgram_Jan27_17.pptxSC Rituximab Nursing Program
SC Rituximab Nursing Program
**Funding for our medical education programs provided by AstraZeneca and Janssen
Tel. 416-434-8923
Email. info@impactmedicom.com